tirzepatide shortage fda says is over after taking a second look fda update on tirzepatide Important
Description
Unlike older weight-loss medications, Wegovy is specially engineered with a long-acting formula, requiring just one injection per week

[DOI] [PMC free article] [PubMed] [Google Scholar] Zhu et al

14 GLP-1 also inhibits NFB activation and modulates the activity of natural killer cells in pancreas, CNS and endothelial cells
Its FDA-approved for chronic weight management in adults with a BMI of 30 or higher, or a BMI of 27 or higher with at least one weight-related condition (including high blood pressure or type 2 diabetes)
While both GLP-1 medications and post-cholecystectomy digestion can involve gastrointestinal symptoms like nausea, diarrhea, or constipation, these dont typically worsen pre-existing post-cholecystectomy issues
